Shanghai Xunhe Pharmaceutical Technology Co. Ltd.

Shanghai Institute of Pharmaceutical Industry

Chengdu Jinrui Foundation Biotech Co., Ltd.

Cspc Zhonggi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.

Koninklijke Philips Electronics N.v.

Cspc Zhongqi Pharmaceutical Technology Co., Ltd.

Hua Jin

Feng Zhou

Xin Zhang

Jianqi Li

Ming Yan

Yongyong Zheng

Meihua Huang

Xin Meng

Nongnong Wei

Zhijie Weng

Na Lv

The present invention relates to the technical field of biomedicine, particularly to a selective dihydropyrrolopyrimidine JAK2 inhibitor or a pharmaceutically acceptable salt thereof. Compared with the prior art, the pyrrolopyrimidine compounds, stereoisomers and pharmaceutically acceptable salts thereof provided by the present invention exhibit better inhibitory activity for Janus Kinase and significantly better selectivity for JAK2 inhibitory targets. In addition, the preferred compounds of the present invention exhibit good pharmacokinetic properties and have the potential to be developed as selective JAK2 inhibitors.

Selective dihydropyrrolopyrimidine JAK2 inhibitors

The present invention relates to the technical field of biomedicine, particularly to a pyridine sulfonamide phosphate compound, a preparation method therefor, and a use thereof. The invention provides the following technical benefits: the pyridine sulfonamide phosphate compound has characteristics of high solubility, high stability, ease of being made into preparations, etc., which is easy to be industrially scaled up for medical use.

Pyridine sulfonamide phosphate compound, preparation method therefor, and use thereof

The present disclosure relates to a 2,4-disubstituted pyrimidine derivative and the use thereof as a therapeutically effective cyclin-dependent kinase (CDK) inhibitor. In particular, the present disclosure relates to the use of a new 2,4-disubstituted pyrimidine derivatives shown in formula (I) and a pharmaceutical composition thereof as a selective CDK4/6 inhibitor in preventing or treating diseases related to CDK4/6. 

2,4-disubstituted pyrimidines as CDK inhibitors

The present invention relates to a heterocyclic-substituted pyridinopyrimidinone derivative and the use thereof as a therapeutically effective cyclin-dependent kinase (CDK) inhibitor. In particular, the present invention relates to the use of a new heterocyclic-substitute pyridinopyrimidinone derivative as shown in formula (I) and a pharmaceutical composition thereof as a selective CDK4/6 inhibitor in preventing or treating diseases related to CDK4/6. 

Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof

The invention discloses 1-butyl-2-hydroxyl aralkyl piperazine derivatives and their use as antidepressants. The derivatives of the present invention have triple inhibition effect on the reuptake of 5-HT, NA and DA, and can be administrated to the patients in need thereof in form of composition by route of oral administration, injection and the like. Compared with clinically currently used dual targets antidepressants (such as venlafaxine), said derivatives may have stronger antidepression effect, broader indications, faster onset and lower neurotoxicity and side reaction; and said derivatives have stronger antidepression activity, lower toxicity, higher bioavailability, longer half life and better druggablity, compared with aryl alkanol piperazine derivatives and optical isomers thereof disclosed in prior art. The 1-butyl-2-hydroxyl aralkyl piperazine derivative is the free alkali or its salt of a compound of formula below: 

1-butyl-2-hydroxyaralkyl piperazine derivatives and the uses as anti-depression medicine thereof

Growing community of inventors

Shanghai, China

Hua Jin